🇺🇸 FDA

Intelligence · Clinical Pipeline

MSD Merck Sharp Pipeline

All ClinicalTrials.gov programs at MSD Merck Sharp — phase, modality, and trial IDs.

Programs
84

Quick answer

MSD Merck Sharp has 84 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. MK-4280A, TRIFLURIDINE, COMBINATIONS, REGORAFENIB

    Merck Sharp and Dohme

    Colorectal Cancer

    phase 3 small molecule active

    1 trial

  2. MK-6194, Placebo for MK-6194

    Merck Sharp and Dohme

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  3. MK-8591A

    Merck Sharp and Dohme

    HIV infection

    phase 3 small molecule active

    1 trial

  4. Microcrystalline cellulose, Sodium Chloride, Magnesium Stearate, MK-0616

    Merck Sharp and Dohme

    Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  5. Molnupiravir Matching placebo tablets, molnupiravir

    Merck Sharp and Dohme

    SARS-CoV-2 (COVID-19) infection

    phase 3 small molecule active

    1 trial

  6. Nemtabrutinib, ACALABRUTINIB , Nemtabrutinib, IBRUTINIB

    Merck Sharp and Dohme

    Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Lymphocytic Leukemia (CLL)

    phase 3 small molecule active

    1 trial

  7. OXALIPLATIN , Placebo to MK-3475, CAPECITABINE , CALCIUM FOLINATE , FLUOROURACIL , CISPLATIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOCETAXEL

    Merck Sharp and Dohme

    Gastric and gastroesophageal junction (GEJ) adenocarcinoma

    phase 3 small molecule active

    1 trial

  8. Olaparib, CISPLATIN , Olaparib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMETREXED , CARBOPLATIN

    Merck Sharp and Dohme

    Stage IV lung cancer condition

    phase 3 small molecule active

    1 trial

  9. Olaparib, ETOPOSIDE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pembrolizumab placebo (saline), Olaparib matching placebo (tablet), CARBOPLATIN , CISPLATIN , Olaparib

    Merck Sharp and Dohme

    Participants with Limited Stage-Small Cell Lung Cancer, who have received no prior anticancer therapy for their disease.

    phase 3 small molecule active

    1 trial

  10. Opevesostat, FLUDROCORTISONE, PREDNISOLONE, DEXAMETHASONE ACETATE, HYDROCORTISONE, FLUDROCORTISONE ACETATE, ABIRATERONE ACETATE, DEXAMETHASONE, ABIRATERONE ACETATE, HYDROCORTISONE, HYDROCORTISONE, ENZALUTAMIDE, HYDROCORTISONE, PREDNISONE, PREDNISONE ACETATE, HYDROCORTISONE

    Merck Sharp and Dohme

    Metastatic castration resistant prostate cancer

    phase 3 small molecule active

    1 trial

  11. PACLITAXEL, CARBOPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, Placebo to MK-7339 100 mg, Placebo to MK-7339 150 mg, Olaparib, PACLITAXEL ALBUMIN-BOUND

    Merck Sharp and Dohme

    Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  12. PARACETAMOL , -, -, CARBOPLATIN , -, MK-2870, PEMETREXED

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  13. PEMETREXED , KEYTRUDA 25 mg/mL concentrate for solution for infusion, PACLITAXEL ALBUMIN-BOUND, CARBOPLATIN , PACLITAXEL , pembrolizumab, CISPLATIN

    Merck Sharp and Dohme

    Metastatic (stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC).

    phase 3 small molecule active

    1 trial

  14. PREDNISOLONE , PREDNISONE , -, Ifinatamab Deruxtecan, PARACETAMOL , -, DOCETAXEL , -, -, -

    Merck Sharp and Dohme

    Metastatic Castration-Resistant Prostate Cancer

    phase 3 small molecule active

    1 trial

  15. Placebo for MK-0616, Placebo for Ezetimibe, EZETIMIBE , BEMPEDOIC ACID , MK-0616, Placebo for Bempedoic Acid

    Merck Sharp and Dohme

    Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  16. Placebo for MK-7240, tulisokibart

    Merck Sharp and Dohme

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

  17. Placebo for pembrolizumab, ENZALUTAMIDE , PEMBROLIZUMAB

    Merck Sharp and Dohme

    Metastatic hormone sensitive prostate cancer

    phase 3 small molecule active

    1 trial

  18. Placebo for pembrolizumab, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE , FLUOROURACIL , OXALIPLATIN , CISPLATIN

    Merck Sharp and Dohme

    Gastric and gastric esophageal junction (GEJ) adenocarcinoma

    phase 3 small molecule active

    1 trial

  19. Placebo to Keytruda - Normal Saline Solution, GEMCITABINE, CISPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Cis-eligible Muscle-invasive bladder cancer.

    phase 3 small molecule active

    1 trial

  20. Placebo to MK-7240 (Tulisokibart), tulisokibart

    Merck Sharp and Dohme

    Crohn’s Disease or Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  21. Placebo to MK-7240, tulisokibart, tulisokibart

    Merck Sharp and Dohme

    Crohn’s Disease

    phase 3 small molecule active

    1 trial

  22. Placebo to Pembrolizumab, CISPLATIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Locally Advanced Cervical Cancer

    phase 3 small molecule active

    1 trial

  23. Placebo to doravirine/ islatravir, MK-8591A, Placebo to bictegravir/ emtricitabine/ tenofovir alafenamide, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, Biktarvy 50 mg/200 mg/25 mg film-coated tablets

    Merck Sharp and Dohme

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  24. Pneumovax® 23 solution for injection in pre-filled syringe Pneumococcal Polysaccharide Vaccine, V110, Pneumococcal 21-valent Conjugate Vaccine

    Merck Sharp and Dohme

    Pneumococcal disease

    phase 3 small molecule active

    1 trial

  25. Raludotatug Deruxtecan

    Merck Sharp and Dohme

    Gastrointestinal Cancers

    phase 3 small molecule active

    1 trial

  26. Rosuvastatin Placebo, MK-0616 (Enlicitide chloride) Placebo, MK-0616, ROSUVASTATIN

    Merck Sharp and Dohme

    Hyperlipidemia

    phase 3 small molecule active

    1 trial

  27. SOTATERCEPT, SOTATERCEPT, sotatercept, sotatercept

    Merck Sharp and Dohme

    ​​Pulmonary Arterial Hypertension (PAH)

    phase 3 small molecule active

    1 trial

  28. Shingrix powder and suspension for suspension for injection Herpes zoster vaccine (recombinant, adjuvanted), Cladribine Placebo, cladribine

    Merck Sharp and Dohme

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  29. TENOFOVIR DISOPROXIL AND EMTRICITABINE , MK-8527 F1, Placebo for MK-8527, Placebo for Emtricitabine/Tenofovir Disoproxil

    Merck Sharp and Dohme

    HIV-1 prevention

    phase 3 small molecule active

    1 trial

  30. Vericiguat, Vericiguat, Vericiguat, Vericiguat

    Merck Sharp and Dohme

    Heart Failure due to Systemic Left Ventricular Systolic Dysfunction

    phase 3 small molecule active

    1 trial

  31. XL092, BELZUTIFAN, XL092, XL092, Placebo to Zanzalintinib

    Merck Sharp and Dohme

    Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  32. mRNA-4157, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    The participants must have a histologically confirmed diagnosis of resectable cSCC as the primary site of malignancy (metastatic skin involvement from another primary cancer or from an unknown primary cancer is not permitted).

    phase 3 small molecule active

    1 trial

  33. mRNA-4157, Saline solution for Placebo to v940 (mrna-4157), KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  34. tulisokibart, Placebo to Subcutaneous or intravenous MK-7240 (Tulisokibart), tulisokibart

    Merck Sharp and Dohme

    Crohn’s Disease

    phase 3 small molecule active

    1 trial

  35. tulisokibart, tulisokibart, Placebo to MK-7240

    Merck Sharp and Dohme

    Ulcerative colitis

    phase 3 small molecule active

    1 trial

  36. xevinapant, Xevinapant Placebo

    Merck Sharp and Dohme

    Resected squamous cell carcinoma of the head and neck

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does MSD Merck Sharp have?

84 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.